Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyAmanda Psyrri, Tanguy Y. Seiwert, Jérôme Fayette et al.|Annals of Oncology|2022Cited by 144
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Tanios Bekaii‐Saab, Hidetoshi Hayashi et al.|Journal of Clinical Oncology|2023Cited by 100
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I studyShunji Takahashi, Noboru Yamamoto, Yasuyuki Kakurai et al.|Cancer Science|2021Cited by 72
Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinomaAkihiro Ohmoto, Shunji Takahashi|Modern Pathology|2021Cited by 40
Japanese Orthopaedic Association (JOA) clinical practice guidelines on the management of soft tissue tumors 2020 - Secondary publicationAkira Kawai, Shintaro Iwata, Nobuhito Araki et al.|Journal of Orthopaedic Science|2022Cited by 34